Haizheng pharmaceutical's class 1 antitumor drug HPPH is about to obtain clinical approval

After obtaining the second phase clinical approval document of the first class new drug, Haizheng Pharmaceutical (600267 SH) another new drug, HPPH, will also be approved for clinical application The company has made great efforts to increase the R & D strategy of innovative drugs According to the website of the State Food and Drug Administration (CFDA), the status of HPPH for APIs and preparations for injection of 1.1 chemical drug applied for clinical application by Haizheng pharmaceutical industry has changed to "approved pending certification" Relevant persons of the company told DZH news that the product is about to be approved for clinical application, and the company is expected to obtain clinical approval documents in the near future HPPH is an anti-tumor photosensitizer declared by Haizheng pharmaceutical in February 2013, and it has entered the special approval channel for innovative drugs Photosensitizer is one of the key factors in photodynamic diagnosis and treatment of tumor It can produce cytotoxin and act on target tissue, which directly determines the effect of diagnosis or treatment to a certain extent HPPH declared by Haizheng Pharmaceutical Co., Ltd is a leading innovative drug in the world, which has not been produced by domestic enterprises or declared by other enterprises In addition to the photosensitizer HPPH, another 1.1 chemical drug of Haizheng Pharmaceutical (hs-25) has also obtained the second phase of clinical trial approval at the end of May this year, and will start the clinical trial soon Hs-25 is mainly used for the treatment of primary hypercholesterolemia and nephrotic hyperlipidemia At present, the drug has been in clinical trials in China and the United States at the same time, and has applied for compound patents in 36 countries / regions around the world Baihua, chairman of Haizheng pharmaceutical, once predicted that if the product can be successfully developed and sold on the market, it could generate billions of sales Haizheng pharmaceutical is a leading API manufacturer in China, and one of the largest production bases of antibiotics and anti-tumor drugs in China At present, it is transforming to high-end preparations In 2013, the profit of Haizheng pharmaceutical preparation business exceeded that of API for the first time, and the transformation has achieved initial results.